FEB 23, 2017 06:00 AM PST

Validation and Commercialization of Liquid Biopsy in a CLIA Lab

C.E. CREDITS: P.A.C.E. CE | Florida CE
  • President and CEO at Biocept
      Mr. Nall has over 25 years of healthcare sales and marketing experience, most recently serving at Clarient Diagnostic Services, Inc. in positions of increasing responsibility from 2002 through August 2013, with his last position being General Manager, North American Sales and Marketing. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after Clarient was acquired in 2010. From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including Impath, American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems. Mr. Nall received a Bachelor of Science degree in Business Administration from Central Missouri State University (now known as the University of Central Missouri).


    Liquid Biopsies are gaining acceptance in the Oncology community as a surrogate or complement to the gold standard of tissue biopsy.  A liquid biopsy provides biomarker information that a physician needs to understand in order to choose the best therapy for a patient. 

    Biocept is a San Diego, CA based company with cutting edge cancer diagnostics developed to capture and analyze circulating tumor cells (CTCs) as well as cell-free circulating tumor DNA (CtDNA).   The company has 18 patents issued on it’s proprietary technology that it uses to perform testing on patient samples through it’s CLIA and CAP accredited laboratory. 

    The company has validated 13 assays and currently markets these tests worldwide. 

    The talk will explain the company’s offerings in detail and also cover key points about the very large opportunity to help patients through liquid biopsy. 

    Learning Objective 1:Reasons why physicians use liquid biopsy today and where the uses are trending for the future

    Learning Objective 2:Biocept technology overview for both CTC and CTDNA capture and biomarker analysis

    Learning Objective 3:Validation results for Biocept Target Selector Assays

    Learning Objective 4: Partners for clinical validation along with publications, poster and abstract overview


    Show Resources
    Loading Comments...